TOKYO - Takeda Pharmaceutical Co. Ltd. has entered into a basic research collaboration with NsGene AS for the development of an encapsulated cell therapy for Parkinson's disease, which will fo
Biogen Idec has agreed to pay $200m up front and up to $475m in milestones to acquire the UK developer of drugs for neuropathic pain Convergence Pharmaceuticals. The target company's most promising pi
A safety review of the first three Alzheimer's disease patients given NsGene 's nerve-growth-factor secreting encapsulated cells has been favourable, and a further three patients have now be includ